3.
MIPD vs. OPD for pancreatic head cancer: prognosis
| References | Ref (25) | Ref (36) | Ref (43) |
MIPD, minimally invasive pancreaticoduodenectomy; OPD, open pancreaticoduodenectomy; BMI, body mass index; ASA, American Society of Anesthesiologists; AJCC, American Joint Committee on cancer; LPD, laparoscopic pancreaticoduodenectomy; NCDB, American National Cancer Database. Outcomes are
or median (range); *, P<0.05.
| |||
| Country | USA | USA | USA |
| Procedures | OPD vs. LPD | OPD vs. LPD | OPD vs. LPD |
| Publication date | 2018 | 2016 | 2014 |
| Inclusion period | 2010−2013 | 1995−2014 | 2008−2013 |
| Single/multiple centers | Multiple, NCDB | Single | Single |
| Type of study | Retrospective | Retrospective | Retrospective |
| Patient number | 1,520 vs. 248 | 193 vs. 58 | 214 vs. 108 |
| Female | 53.6% vs. 46.8% | 50.3% vs. 44.8% | 39% vs. 53%* |
| Age (year) | >75, 100%, 79.6vs. 79.5 | 68.9 (33.3−86.9)vs. 69.9 (40.6−84.8) | 65±11 vs. 67±10 |
| BMI (kg/m2) | − | 25.6 (15.0−46.1)vs. 25.9 (17.7−49.6) | 27±5 vs. 27±5 |
| ASA classification | − | >3, 79.7%vs. 72.4%* | − |
| Tumor size (mm) | >4 cm, 21.6%vs. 19.8% | 35 (3−140)vs. 25 (3−100)* | 33±13 vs. 33±10 |
| AJCC stage 1+2 | 86.8% vs. 92.2% | 96.8% vs. 98.3% | − |
| R0 rate | 73.0% vs. 77.4% | 79.8% vs. 84.5% | 77% vs. 78% |
| Resected lymph nodes | >10, 67.8%vs. 69.0% | 17 (1−63)vs. 27 (9−70)* | 20±8 vs. 21±8 |
| Neoadjuvant chemotherapy | 9.7% vs. 6.6% | − | 14.0% vs. 11.1% |
| Neoadjuvant radiation | 3.9% vs. 5.7% | − | − |
| Adjuvant therapy | 36.0% vs. 35.9% | 73.5% vs. 75.9% | 76% vs. 76% |
| Survival time (month) | 15.6 vs. 19.8* | 20.3 vs. 18.5 | 21.8 vs. 25.3 |